Search Results - "DeAngelo, D"

Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy by Montero, Joan, Sarosiek, Kristopher A., DeAngelo, Joseph D., Maertens, Ophélia, Ryan, Jeremy, Ercan, Dalia, Piao, Huiying, Horowitz, Neil S., Berkowitz, Ross S., Matulonis, Ursula, Jänne, Pasi A., Amrein, Philip C., Cichowski, Karen, Drapkin, Ronny, Letai, Anthony

“…There is a lack of effective predictive biomarkers to precisely assign optimal therapy to cancer patients. While most efforts are directed at inferring drug…”
Get full text

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia by Stone, R M, Fischer, T, Paquette, R, Schiller, G, Schiffer, C A, Ehninger, G, Cortes, J, Kantarjian, H M, DeAngelo, D J, Huntsman-Labed, A, Dutreix, C, del Corral, A, Giles, F

“…This phase 1b trial investigated several doses and schedules of midostaurin in combination with daunorubicin and cytarabine induction and high-dose cytarabine…”
Get full text

Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial by DeAngelo, D J, George, T I, Linder, A, Langford, C, Perkins, C, Ma, J, Westervelt, P, Merker, J D, Berube, C, Coutre, S, Liedtke, M, Medeiros, B, Sternberg, D, Dutreix, C, Ruffie, P-A, Corless, C, Graubert, T J, Gotlib, J

“…Patients with advanced systemic mastocytosis (SM) (e.g. aggressive SM (ASM), SM with an associated hematologic neoplasm (SM-AHN) and mast cell leukemia (MCL))…”
Get full text

Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia by DeAngelo, D J, Stevenson, K E, Dahlberg, S E, Silverman, L B, Couban, S, Supko, J G, Amrein, P C, Ballen, K K, Seftel, M D, Turner, A R, Leber, B, Howson-Jan, K, Kelly, K, Cohen, S, Matthews, J H, Savoie, L, Wadleigh, M, Sirulnik, L A, Galinsky, I, Neuberg, D S, Sallan, S E, Stone, R M

“…On the basis of the data suggesting that adolescents and young adult patients with acute lymphoblastic leukemia (ALL) have improved outcomes when treated on…”
Get full text

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts by Garcia-Manero, G, Sekeres, M A, Egyed, M, Breccia, M, Graux, C, Cavenagh, J D, Salman, H, Illes, A, Fenaux, P, DeAngelo, D J, Stauder, R, Yee, K, Zhu, N, Lee, J-H, Valcarcel, D, MacWhannell, A, Borbenyi, Z, Gazi, L, Acharyya, S, Ide, S, Marker, M, Ottmann, O G

“…Treatment with azacitidine (AZA), a demethylating agent, prolonged overall survival (OS) vs conventional care in patients with higher-risk myelodysplastic…”
Get full text

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies by DeAngelo, D J, Spencer, A, Bhalla, K N, Prince, H M, Fischer, T, Kindler, T, Giles, F J, Scott, J W, Parker, K, Liu, A, Woo, M, Atadja, P, Mishra, K K, Ottmann, O G

“…Panobinostat is a potent oral pandeacetylase inhibitor that leads to acetylation of intracellular proteins, inhibits cellular proliferation and induces…”
Get full text

Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503) by Blum, W, Sanford, B L, Klisovic, R, DeAngelo, D J, Uy, G, Powell, B L, Stock, W, Baer, M R, Kolitz, J E, Wang, E S, Hoke, E, Mrózek, K, Kohlschmidt, J, Bloomfield, C D, Geyer, S, Marcucci, G, Stone, R M, Larson, R A

“…In this prospective phase 2 clinical trial conducted by Cancer and Leukemia Group B (CALGB, now the Alliance), we studied decitabine as maintenance therapy for…”
Get full text

Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy by DeAngelo, D J

“…The outcomes for patients with chronic myeloid leukemia have improved dramatically with the development and availability of BCR–ABL1 tyrosine kinase inhibitors…”
Get full text

HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia by Akahane, K, Sanda, T, Mansour, M R, Radimerski, T, DeAngelo, D J, Weinstock, D M, Look, A T

“…We previously found that tyrosine kinase 2 (TYK2) signaling through its downstream effector phospho-STAT1 acts to upregulate BCL2, which in turn mediates…”
Get full text

SYK regulates mTOR signaling in AML by Carnevale, J, Ross, L, Puissant, A, Banerji, V, Stone, R M, DeAngelo, D J, Ross, K N, Stegmaier, K

“…Spleen tyrosine kinase (SYK) was recently identified as a new target in acute myeloid leukemia (AML); however, its mechanistic role in this disease is poorly…”
Get full text

A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma by Papayannidis, C, DeAngelo, D J, Stock, W, Huang, B, Shaik, M N, Cesari, R, Zheng, X, Reynolds, J M, English, P A, Ozeck, M, Aster, J C, Kuo, F, Huang, D, Lira, P D, McLachlan, K R, Kern, K A, Garcia-Manero, G, Martinelli, G

Get full text

Ponatinib-induced pityriasiform, folliculocentric and ichthyosiform cutaneous toxicities by Alloo, A., Sheu, J., Butrynski, J.E., DeAngelo, D.J., George, S., Murphy, G.F., LeBoeuf, N.R.

Get full text

The role of Lin28b in myeloid and mast cell differentiation and mast cell malignancy by Wang, L D, Rao, T N, Rowe, R G, Nguyen, P T, Sullivan, J L, Pearson, D S, Doulatov, S, Wu, L, Lindsley, R C, Zhu, H, DeAngelo, D J, Daley, G Q, Wagers, A J

“…Mast cells (MCs) are critical components of the innate immune system and important for host defense, allergy, autoimmunity, tissue regeneration and tumor…”
Get full text

Independent transcriptomic and proteomic regulation by type I and II protein arginine methyltransferases by Maron, Maxim I., Lehman, Stephanie M., Gayatri, Sitaram, DeAngelo, Joseph D., Hegde, Subray, Lorton, Benjamin M., Sun, Yan, Bai, Dina L., Sidoli, Simone, Gupta, Varun, Marunde, Matthew R., Bone, James R., Sun, Zu-Wen, Bedford, Mark T., Shabanowitz, Jeffrey, Chen, Hongshan, Hunt, Donald F., Shechter, David

“…Protein arginine methyltransferases (PRMTs) catalyze the post-translational monomethylation (Rme1), asymmetric (Rme2a), or symmetric (Rme2s) dimethylation of…”
Get full text

Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes by Swords, R T, Watts, J, Erba, H P, Altman, J K, Maris, M, Anwer, F, Hua, Z, Stein, H, Faessel, H, Sedarati, F, Dezube, B J, Giles, F J, Medeiros, B C, DeAngelo, D J

Get full text

On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia by Feldman, E J, Cortes, J, DeAngelo, D J, Holyoake, T, Simonsson, B, O'Brien, S G, Reiffers, J, Turner, A R, Roboz, G J, Lipton, J H, Maloisel, F, Colombat, P, Martinelli, G, Nielsen, J L, Petersdorf, S, Guilhot, F, Barker, J, Kirschmeier, P, Frank, E, Statkevich, P, Zhu, Y, Loechner, S, List, A

“…Lonafarnib is an orally bio-available farnesyltransferase inhibitor that prevents farnesylation of specific target proteins including Ras. In a multicenter…”
Get full text

KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32) by LEVINE, R. L, WADLEIGH, M, STERNBERG, D. W, WLODARSKA, I, GALINSKY, I, STONE, R. M, DEANGELO, D. J, GILLILAND, D. Gary, COOLS, J

“…We report the cloning of a novel PDGFRB fusion gene partner in a patient with a chronic myeloproliferative disorder characterized by t(5;14)(q33;q32), who…”
Get full text

Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies by Ravandi, F, Pigneux, A, DeAngelo, D J, Raffoux, E, Delaunay, J, Thomas, X, Kadia, T, Kantarjian, H, Scheuenpflug, J, Zhao, C, Guo, W, Smith, B D

Get full text

PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY by Daver, N. G., Wei, A. H., Stein, E. M., DeAngelo, D. J., Pathak, D., Xu, Y., Grzesiak, S., Venditti, A.

Get full text

P1027: RESPONSES TO AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: HISTOPATHOLOGIC ANALYSES FROM EXPLORER AND PATHFINDER CLINICAL STUDIES by George, T., Karner, K. H., Moser, K. A., Rets, A., Reiter, A., Radia, D. H., Deininger, M., Lin, H.‐M., Dimitrijević, S., DeAngelo, D. J.

Get full text